We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

38 hedge funds and large institutions have $12.6M invested in Lisata Therapeutics in 2014 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

15% more funds holding

Funds holding: 33 → 38 (+5)

7% less capital invested

Capital invested by funds: $13.6M → $12.6M (-$952K)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

51% less call options, than puts

Call options by funds: $777K | Put options by funds: $1.59M

Holders
38
Holders Change
+5
Holders Change %
+15.15%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
8
Reduced
9
Closed
7
Calls
$777K
Puts
$1.59M
Net Calls
-$816K
Net Calls Change
-$357K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$644K
2
RJA
Raymond James & Associates
Florida
+$472K
3
U
UBS
Switzerland
+$459K
4
Jane Street
Jane Street
New York
+$450K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$377K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$1.57M
2
IHM
Iguana Healthcare Management
New York
-$1.45M
3
SC
Sophrosyne Capital
New York
-$963K
4
Morgan Stanley
Morgan Stanley
New York
-$220K
5
Group One Trading
Group One Trading
Illinois
-$177K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
26
Guggenheim Capital
Illinois
$86K +$87.8K +81 New
RCM
27
Rotella Capital Management
Washington
$80K +$82.4K +76 New
Wells Fargo
28
Wells Fargo
California
$53K +$53.1K +49 +4,900%
BG
29
BlackRock Group
United Kingdom
$43K +$44.5K +41 New
Barclays
30
Barclays
United Kingdom
$36K +$35.8K +33 +3,300%
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$26K – – –
Citigroup
32
Citigroup
New York
$21K -$5.42K -5 -20%
JIC
33
Joel Isaacson & Co
New York
$11K – – –
TRCT
34
Tower Research Capital (TRC)
New York
$7K -$36.9K -34 -83%
AllianceBernstein
35
AllianceBernstein
Tennessee
$6K -$1.08K -1 -17%
BIT
36
BlackRock Institutional Trust
California
$4K +$4.34K +4 New
Ameriprise
37
Ameriprise
Minnesota
$2K – – –
Manulife (Manufacturers Life Insurance)
38
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1 -$10.8K -10 -91%
PRCM
39
Pine River Capital Management
Minnesota
– -$46K -2,542 Closed
PA
40
Perceptive Advisors
New York
– -$1.57M -1,531 Closed
SC
41
Sophrosyne Capital
New York
– -$963K -941 Closed
Group One Trading
42
Group One Trading
Illinois
– -$177K -163 Closed
OAM
43
Oxford Asset Management
United Kingdom
– -$103K -101 Closed
VKH
44
Virtu KCG Holdings
New York
– -$103K -101 Closed
Northwestern Mutual Wealth Management
45
Northwestern Mutual Wealth Management
Wisconsin
– -$3K -3 Closed
1
2

LSTA Hedge Fund Activity: Q1 2014 in Review

38 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2014, worth a combined $12.6M — down 7% from $13.6M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new LSTA positions and 7 closed out — a net gain of 5 holders — while 8 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $644K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.57M sold.

  • 38 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2014, up from 33 in Q4 2013.
  • Funds reported $12.6M of Lisata Therapeutics stock for Q1 2014, down 7% quarter-over-quarter.
  • 12 funds opened new Lisata Therapeutics positions in Q1 2014 and 7 closed out, a net change of +5 holders.
  • The largest Lisata Therapeutics buyer in Q1 2014 was Vanguard Group, an estimated $644K added.
  • The largest Lisata Therapeutics seller in Q1 2014 was Perceptive Advisors, an estimated $1.57M sold.

Based on aggregated 13F filings for Q1 2014.